Hims pivots to branded Tirzepatide, generic Liraglutide
Hims changes to selling branded Tirzepatide along with the Liraglutide generic on their telehealth platform, after the shortage ends.
- "branded Wegovy" will also be sold by Hims
- Pricing discussions
Most people have been having the unfortunate experience of a stop of service from compounding pharmacies that used to serve them. While of course people are suffering the most, popular telehealth provider and compounded GLP1 market participant Hims's stock has tumbled following the news:
While Hims leaned heavily into compounded GLP1s (Semaglutide and Tirzepatide), the recent change in shortage status meant that their revenues could not continue.
This left a question of what Hims would do next – and it looks like there is clarity on that now:
It's still unclear how Hims plans to obtain Tirzepatide (Zepbound) – where as in the past they could rely on compounding, that option is now gone.
Want to read more about the ruckus between Eli Lilly and Hims? The rest of this article is no longer available for free – if you'd like to read the rest of our analysis, check us out on Substack:
